Ocugen, Inc. (OCGN)
NASDAQ: OCGN · Real-Time Price · USD
0.680
-0.020 (-2.88%)
At close: Feb 21, 2025, 4:00 PM
0.690
+0.010 (1.46%)
After-hours: Feb 21, 2025, 7:58 PM EST
Ocugen Employees
Ocugen had 65 employees as of December 31, 2023. The number of employees decreased by 19 or -22.62% compared to the previous year.
Employees
65
Change (1Y)
-19
Growth (1Y)
-22.62%
Revenue / Employee
$72,308
Profits / Employee
-$786,831
Market Cap
198.48M
Employees Chart
Related Stocks
| Company Name | Employees |
|---|---|
| UnitedHealth Group | 440,000 |
| Johnson & Johnson | 131,900 |
| Thermo Fisher Scientific | 125,000 |
| Abbott Laboratories | 114,000 |
| AstraZeneca | 92,900 |
| Novo Nordisk | 77,349 |
| Novartis AG | 75,883 |
| Merck & Co. | 72,000 |
OCGN News
- 1 day ago - Ocugen to Host Conference Call on Wednesday, March 5, 2025 at 8:30 A.M. ET to Discuss Business Updates and Fourth Quarter and Full Year 2024 Financial Results - GlobeNewsWire
- 10 days ago - Ocugen, Inc. Announces Dosing Completion in the Phase 2 ArMaDa Clinical Trial for OCU410—a Multifunctional Modifier Gene Therapy for the Treatment of Geographic Atrophy Secondary to Dry Age-Related Macular Degeneration - GlobeNewsWire
- 19 days ago - Ocugen Announces Positive Opinion of European Medicines Agency's Committee for Advanced Therapies for Advanced Therapy Medicinal Product Classification for Modifier Gene Therapy Candidate OCU400 for Retinitis Pigmentosa - GlobeNewsWire
- 26 days ago - Ocugen, Inc. Announces Investigational New Drug Application in Effect After Review by FDA to Initiate Phase 1 Clinical Trial Evaluating First-in-Class OCU500 Inhaled Vaccine Candidate for COVID-19 - GlobeNewsWire
- 5 weeks ago - Ocugen, Inc. Announces First Patient Dosed in Phase 1 Clinical Trial of OCU200—a Novel Integrin-Targeting Biologic for Diabetic Macular Edema - GlobeNewsWire
- 5 weeks ago - Ocugen, Inc. Announces Positive 2-Year Data Across Multiple Mutations from Phase 1/2 Clinical Trial of OCU400 —A Novel Modifier Gene Therapy for Retinitis Pigmentosa - GlobeNewsWire
- 2 months ago - Data and Safety Monitoring Board Reviews Interim Safety Data of Phase 2 Subjects of OCU410 ArMaDa Clinical Trial for Geographic Atrophy Secondary to Dry Age-Related Macular Degeneration - GlobeNewsWire
- 2 months ago - Ocugen CEO to Present at Oppenheimer Movers in Rare Disease Summit - GlobeNewsWire